TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26416606

Group type: EXPERIMENTAL
Intervention: Walk Well program
Number of subjects: 102

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 102
Study: 23551956

Group type: EXPERIMENTAL
Intervention: Rasagiline mesylate (1 mg) once daily
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 21962461

Group type: EXPERIMENTAL
Intervention: Group treatment sessions (GT) of pelvic floor muscle training (PFMT) for 6 weeks, with two 1-hour sessions per week.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Individual treatment sessions (IT) of pelvic floor muscle training (PFMT) for 6 weeks, with two 1-hour sessions per week.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (CG) with no treatment during the corresponding time.
Number of subjects: 49
Study: 17360209

Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol (1.25mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (2.5mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 16429430

Group type: EXPERIMENTAL
Intervention: Dead Sea (barometric pressure, 791 +/- 3 mmHg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sea level (barometric pressure, 754 +/- 6 mmHg)
Number of subjects: 14
Study: 12624628

Group type: EXPERIMENTAL
Intervention: Warfarin (long half-life)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Acenocoumarol (short half-life)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Intensive education
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 86
Study: 10673512

Group type: EXPERIMENTAL
Intervention: IM862 intranasal drops at a dose of 5 mg, given in two dosing schedules: 5 days on, 5 days off (n = 18)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IM862 intranasal drops at a dose of 5 mg, given every other day (n = 26)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: IM862 intranasal drops
Number of subjects: 44
Study: 8862237

Group type: EXPERIMENTAL
Intervention: Dietary intervention group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 228
Study: 1993279

Group type: EXPERIMENTAL
Intervention: Ethoglucid (0.565 g, 1% solution) weekly for 6 weeks, then monthly for 1 year
Number of subjects: 77

Group type: COMPARATOR
Intervention: Keyhole-limpet haemocyanin (KLH) 1 mg subcutaneously, followed by bladder instillations of 30 mg weekly for 6 weeks, then monthly for 1 year
Number of subjects: 77
Study: 6394516

Group type: EXPERIMENTAL
Intervention: 50 mg captopril
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 500 mg methyldopa
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.5 mg indapamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29143355

Group type: EXPERIMENTAL
Intervention: Oral appliances with an occlusal flat table
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no oral-appliance insertion)
Number of subjects: 20
Study: 26964901

Group type: EXPERIMENTAL
Intervention: 30 mg/mL ketorolac buccal infiltration
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline buccal infiltration (control group)
Number of subjects: 40
Study: 25823187

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training on a bicycle ergometer for 15 minutes, three times a week at 50-60% of maximal heart rate
Number of subjects: 80

Group type: COMPARATOR
Intervention: No exercise training (Control)
Number of subjects: 80
Study: 22906948

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 94

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 94

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 94
Study: 19675960

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy plus Motivational Interviewing (CBT + MI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy plus Psychoeducation (CBT + PE)
Number of subjects: 16
Study: 18714219

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3‐) ingestion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 15671428

Group type: EXPERIMENTAL
Intervention: GIK infusion for 24 hours plus usual care (n = 10,091)
Number of subjects: 20201

Group type: COMPARATOR
Intervention: Usual care alone (controls; n = 10,110)
Number of subjects: 20201
Study: 12912814

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 10585975

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment (1 mg/kg/day for 9 days followed by 0.5 mg/kg/day for 3 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8923547

Group type: EXPERIMENTAL
Intervention: BB (all black)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MA (matched)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPP (opposite)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BW (one side black, the other white)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPP patterns progressively changed into BB patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonmatched polarity
Number of subjects: 0
Study: 1832261

Group type: EXPERIMENTAL
Intervention: Atropine (8 micrograms.kg‐1 each, two doses with 1 min interval)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Glycopyrrolate (7 micrograms.kg‐1, single dose)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Glycopyrrolate
Number of subjects: 55
Study: 6619271

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg, iv) administered at 1100 h
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg, iv) administered at 2300 h
Number of subjects: 21
Study: 6376722

Group type: COMPARATOR
Intervention: melphalan (8 mg/m2 perorally for four days) and prednisone (40 mg/m2 perorally for seven days, both every four weeks)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: melphalan and prednisone at the same doses plus cyclophosphamide (600 mg/m2 intravenously every four weeks), MeCCNU (100 mg/m2 PO every eight weeks), and vincristine (0.6 mg/m2 IV every four weeks)
Number of subjects: 234
Study: 30132244

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 469

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 469
Study: 26611332

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 75
Study: 24944134

Group type: EXPERIMENTAL
Intervention: Football training (FG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 57
Study: 21945362

Group type: EXPERIMENTAL
Intervention: Synthetic melatonin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 20197012

Group type: EXPERIMENTAL
Intervention: EPs 7630 (1-6 years: 3 x 10 drops/d; > 6-12 years: 3 x 20 drops/d; > 12-18 years: 3 x 30 drops/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: EPs 7630
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 18502109

Group type: EXPERIMENTAL
Intervention: Gemfibrozil for HTG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atorvastatin or Simvastatin for HCHL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three drugs (Atorvastatin, Simvastatin, Gemfibrozil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 0
Study: 15818718

Group type: EXPERIMENTAL
Intervention: Patient-reported data from health economic questionnaire
Number of subjects: 234

Group type: COMPARATOR
Intervention: Payer-derived data from insurance claims
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Both patient-reported and payer-derived data
Number of subjects: 234
Study: 12766097

Group type: EXPERIMENTAL
Intervention: Dermagraft
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control (conventional therapy)
Number of subjects: 314
Study: 10571355

Group type: EXPERIMENTAL
Intervention: Topical anesthesia plus 0.5 ml preservative-free 1% intracameral lidocaine
Number of subjects: 204

Group type: COMPARATOR
Intervention: Topical anesthesia plus 0.5 ml intracameral balanced salt solution
Number of subjects: 204
Study: 8545227

Group type: EXPERIMENTAL
Intervention: RRV-1 (monovalent serotype 1)
Number of subjects: 1278

Group type: EXPERIMENTAL
Intervention: RRV-TV (tetravalent)
Number of subjects: 1278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1278
Study: 1859055

Group type: EXPERIMENTAL
Intervention: Oral killed Haemophilus influenzae vaccine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 6138009

Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride 60 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride 90 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buspirone hydrochloride (30, 60, 90 mg)
Number of subjects: 0
Study: 31290965

Group type: COMPARATOR
Intervention: Esketamine 84 mg plus oral antidepressant
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Esketamine 56 mg plus oral antidepressant
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo plus oral antidepressant
Number of subjects: 346
Study: 28816150

Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg with WBRT (n=5)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg with SRS (n=11)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 16
Study: 25413313

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) in 27 patients with LVI-positive tumors.
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Lymphovascular invasion (LVI) presence in tumors.
Number of subjects: 499
Study: 23825035

Group type: EXPERIMENTAL
Intervention: 12-week Iyengar yoga program (twice weekly) with fall prevention education booklet
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (education booklet only)
Number of subjects: 54
Study: 21752945

Group type: EXPERIMENTAL
Intervention: Determine HIV‐1/2 assay
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Confirmatory testing results at ITM
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Second blood specimen testing
Number of subjects: 1398

Group type: EXPERIMENTAL
Intervention: Testing algorithm with R/S assays
Number of subjects: 1398
Study: 19358730

Group type: EXPERIMENTAL
Intervention: Primary care visit with physician discussion about alcohol
Number of subjects: 173
Study: 16971315

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg for 3 consecutive days a week for 1 month, then 250 mg every other day for 2 months
Number of subjects: 290

Group type: COMPARATOR
Intervention: Tetracycline 1 g daily for 1 month, then 500 mg daily for 2 months
Number of subjects: 290
Study: 15179210

Group type: EXPERIMENTAL
Intervention: Beta-blocker (Metoprolol)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 11722956

Group type: COMPARATOR
Intervention: Methionine intake of 0 mg x kg(‐1) x d(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methionine intake of 6.5 mg x kg(‐1) x d(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methionine intake of 13.0 mg x kg(‐1) x d(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methionine intake of 19.5 mg x kg(‐1) x d(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methionine intake of 26.0 mg x kg(‐1) x d(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methionine intake of 32.0 mg x kg(‐1) x d(‐1)
Number of subjects: 6
Study: 9463982

Group type: EXPERIMENTAL
Intervention: Formulary for NSAIDs
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 10
Study: 8162931

Group type: EXPERIMENTAL
Intervention: Ventilation-perfusion lung scintigraphy interpretation by experienced clinical physiologists
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Simple scheme for deciding segmental ventilation-perfusion mismatch
Number of subjects: 87
Study: 3145358

Group type: EXPERIMENTAL
Intervention: Postoperative radiation with increased doses from 36 to 46 Gy and accelerated split course hyperfractionation with simultaneous chemotherapy.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional fractionation of radiotherapy (control group).
Number of subjects: 76
Study: 31226721

Group type: EXPERIMENTAL
Intervention: Revacept 160 mg
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Revacept 80 mg
Number of subjects: 332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Revacept 160 mg, Revacept 80 mg, or Placebo
Number of subjects: 332
Study: 27930611

Group type: EXPERIMENTAL
Intervention: Community mobilization intervention in intervention villages
Number of subjects: 2356

Group type: COMPARATOR
Intervention: Control group (no community mobilization intervention)
Number of subjects: 2356
Study: 25532433

Group type: EXPERIMENTAL
Intervention: Modified D2 lymphadenectomy (D1+)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Standard D2 lymphadenectomy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 73
Study: 22460183

Group type: EXPERIMENTAL
Intervention: Corticosteroids and azathioprine (3 intravenous pulses of methylprednisolone 1 g at months 1, 3, and 5; oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for 6 months, followed by oral prednisone 0.2 mg/kg every other day plus azathioprine 50 mg/day for a further 6 months)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Corticosteroids alone (26 patients)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Both groups (whole population)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Corticosteroids and azathioprine (group 1)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Corticosteroids alone (group 2)
Number of subjects: 253
Study: 21570870

Group type: EXPERIMENTAL
Intervention: Batroxobin plus aspirin (5 IU every other day for six doses)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Aspirin alone (100 mg/d)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Batroxobin plus aspirin
Number of subjects: 129

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 129
Study: 18496519

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 17215606

Group type: EXPERIMENTAL
Intervention: Infant massage (auditory, tactile/kinesthetic, and visual stimulation) for 4 weeks
Number of subjects: 52
Study: 12627740

Group type: EXPERIMENTAL
Intervention: Skills training (ST)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 229
Study: 11180027

Group type: EXPERIMENTAL
Intervention: 10 mg/70 kg of morphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3.3 mg/70 kg of M6G
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30.6 mg/70 kg of M3G
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30.6 mg/70 kg of M3G with 10 mg/70 kg of morphine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30.6 mg/70 kg of M3G with 3.3 mg/70 kg of M6G
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9382506

Group type: EXPERIMENTAL
Intervention: Postoperative 50 Gy radiation therapy to pelvic wall
Number of subjects: 110

Group type: COMPARATOR
Intervention: No radiation therapy
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Postoperative complications in radiation therapy group
Number of subjects: 110
Study: 8436755

Group type: EXPERIMENTAL
Intervention: Spectral measures of heart period variability (RR variability)
Number of subjects: 0
Study: 3706373

Group type: EXPERIMENTAL
Intervention: Reassurance debriefing
Number of subjects: 296

Group type: COMPARATOR
Intervention: Traditional arousal debriefing
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Worksite health education programs
Number of subjects: 296

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Baseline anxiety levels
Number of subjects: 296
Study: 29127153

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope
Number of subjects: 45

Group type: COMPARATOR
Intervention: Laryngoscope
Number of subjects: 45
Study: 26995778

Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 28
Study: 24886037

Group type: EXPERIMENTAL
Intervention: Navicular Drop Test (NDT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ankle Joint Dorsiflexion Test (AJD)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Extension MTP1 Test
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of female and male runners
Number of subjects: 42
Study: 22789149

Group type: EXPERIMENTAL
Intervention: Patient communication skill training
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Physician communication skill training
Number of subjects: 194
Study: 21099157

Group type: EXPERIMENTAL
Intervention: CPN applied for 30 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPN applied for 20 seconds followed by water rinsing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Etching with 10% citric acid‐3% FeCl(3) solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPN applied for 10, 20, 30, or 60 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming with CPN for 10, 20, 30, or 60 seconds followed by etching
Number of subjects: 0
Study: 18503922

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 22

Group type: COMPARATOR
Intervention: Off-pump CABG
Number of subjects: 22
Study: 15897362

Group type: EXPERIMENTAL
Intervention: Ramipril, 10 mg once daily for 24 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ramiprilat in cell culture
Number of subjects: 40
Study: 14570950

Group type: EXPERIMENTAL
Intervention: 250 mg gefitinib
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 500 mg gefitinib
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Both doses of gefitinib
Number of subjects: 221
Study: 10364865

Group type: EXPERIMENTAL
Intervention: Sevoflurane + Alfentanil (5 micrograms.kg‐1)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Propofol + Alfentanil (5 micrograms.kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Propofol (2.5 mg.kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sevoflurane (> 7% in the inspiratory gas)
Number of subjects: 100
Study: 8678385

Group type: EXPERIMENTAL
Intervention: ipratropium bromide nasal spray 0.06% (two 42-micrograms sprays per nostril)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: ipratropium bromide nasal spray 0.06%
Number of subjects: 411
Study: 8500918

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3540301

Group type: EXPERIMENTAL
Intervention: Small-group instruction in addition to large-group lectures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Large-group lectures only
Number of subjects: 0
Study: 30842084

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment for more than 5 years
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 10
Study: 29342952

Group type: EXPERIMENTAL
Intervention: Nacadia® nature-based therapy (NNBT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (STreSS)
Number of subjects: 84
Study: 27724992

Group type: EXPERIMENTAL
Intervention: Oral spray vitamin D3 (3000 IU daily for 4 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Capsule vitamin D3 (3000 IU daily for 4 weeks)
Number of subjects: 22
Study: 26228164

Group type: EXPERIMENTAL
Intervention: Collaborative care anxiety management program
Number of subjects: 503
Study: 23597332

Group type: EXPERIMENTAL
Intervention: Labeled group (informed of prehypertension)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unlabeled group (not informed of prehypertension)
Number of subjects: 100
Study: 20873898

Group type: EXPERIMENTAL
Intervention: Family group cognitive-behavioral preventive intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Written information comparison condition
Number of subjects: 111
Study: 18441679

Group type: EXPERIMENTAL
Intervention: Fenspiride in combination with broncholytic drugs for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard treatment for COPD
Number of subjects: 68
Study: 16800987

Group type: EXPERIMENTAL
Intervention: ursodesoxycholic acid (UDA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: combination of LDL and UDA (LDL + UDA)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lidanling (LDL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Not applicable (Control group)
Number of subjects: 27
Study: 12684720

Group type: EXPERIMENTAL
Intervention: Approximate planimetric method (APM) for estimating lesion size using DWI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Approximate planimetric method (APM) for estimating lesion size using FLAIR
Number of subjects: 40
Study: 10231255

Group type: EXPERIMENTAL
Intervention: Educational package intervention
Number of subjects: 1001

Group type: COMPARATOR
Intervention: Control group (no educational package)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Tranexamic acid with norethisterone
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Practices with fewer than 10 cases
Number of subjects: 1001
Study: 7702138

Group type: EXPERIMENTAL
Intervention: Double burst stimulation with vecuronium 0.2 mg.kg‐1 in group A
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Double burst stimulation with vecuronium 0.2 mg.kg‐1 in group B
Number of subjects: 60
Study: 2568783

Group type: EXPERIMENTAL
Intervention: Iotrolan 190
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cerebrospinal fluid-diluted iotrolan 300
Number of subjects: 100
Study: 578480

Group type: EXPERIMENTAL
Intervention: 1 g ASA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10